MRK: Message Board for Merck and Co., Inc. - InvestorVillage


Merck and Co., Inc.

  MRK website

MRK   /  Message Board

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
MSG # SUBJECT TYPE AUTHOR SENTIMENT RECS DATE POSTED
584 HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA's Fast Track Designation GN jerrykrause 0 1/20/2022 1:23:27 PM
583 Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA for Treatment of Melanoma GN jerrykrause 0 1/20/2022 1:14:49 PM
582 Keytruda reimbursement boosts MSD's R&D of follow-up drug GN jerrykrause 0 1/17/2022 12:59:45 PM
581 Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH GN jerrykrause 0 1/13/2022 12:16:44 PM
580 I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors GN jerrykrause 0 1/13/2022 12:13:28 PM
579 Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA (pembrolizumab) GN jerrykrause 0 1/11/2022 7:30:11 PM
578 Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combination With KEYTRUDA in First-Line Metastatic Non-Small Cell Lung Cancer GN jerrykrause 0 1/11/2022 7:11:42 PM
577 80 GN nealhugh Hold 0 1/8/2022 9:11:27 PM
576 Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis GN jerrykrause 1 1/6/2022 7:37:17 PM
575 Merck to acquire rights to develop cladribine for myasthenia gravis, NMOSD GN jerrykrause 0 12/24/2021 2:09:12 PM
Previous 566 Messages Top of Message List Post Message Go to Msg #  


Financial Market Data provided by
.
Loading...